Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Evofem Biosciences, Inc.NEOT · Entity 8607 | VP, Clinical Research | June 22, 2017 | June 23, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Evofem Biosciences, Inc.
Report date June 22, 2017 · Filed June 23, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.27 · Expires 2027-06-22 | Direct | 140,000 |
Reported balance
After 2017-06-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-06-22 · Grant · Acquired 140,000 · Balance 140,000 F1: Option shares vest and become exercisable in twenty-four (24) successive equal monthly installments measured from June 22, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: Option shares vest and become exercisable in twenty-four (24) successive equal monthly installments measured from June 22, 2017.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 22, 2017 Filed Jun 23, 2017 16:00 UTC | Evofem Biosciences, Inc. NEOT · Entity 8607 | GrantEmployee Stock Option (Right to Buy) · Derivative | 140,000 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001209191-17-041626 · doc4.xml · derivative · entry 1 Feldman Maria · CIK 0001674083 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2027-06-22 F1 · derivative.exercise_date: Option shares vest and become exercisable in twenty-four (24) successive equal monthly installments measured from June 22, 2017. Read SEC document |
| March 02, 2017 Filed Mar 6, 2017 15:55 UTC | Evofem Biosciences, Inc. NEOT · Entity 8607 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0001618835-17-000002 · primary_doc.xml · derivative · entry 1 Feldman Maria · CIK 0001674083 · VP Clinical Research & Operati 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2027-03-02 F1 · derivative.exercise_date: (i) One half of the option shares vest upon receipt and completed analysis of LIPO-202 CL-31 trial data and (ii) the remaining one half of the option shares vest at the earlier of (a) 12/31/2017 or (b) upon the event of a change in control. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.